Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rosetta Genomics' microRNA-based test, miRview mets² has secured approval from the New York State Department of Health (DOH).
Subscribe to our email newsletter
The test identifies the primary origin of many types of tumors of uncertain or unknown origin and facilitates physicians by confirming suspected origins, or providing possible new origins to explore which can affect treatment options.
In addition, it also identifies sarcomas, lymphomas and other non-epithelial malignancies, as well as more histologic subtypes.
miRview mets² provides physicians and patients a portfolio of 42 identifiable tumor origins and biologically motivated proprietary classifiers to effectively direct the diagnostic process.